| Symbol | INCY |
|---|---|
| Name | INCYTE CORP |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Services-Commercial Physical & Biological Research |
| Address | 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE 19803 |
| Telephone | 3024986700 |
| Fax | — |
| — | |
| Website | https://www.incyte.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000879169 |
| Description | Incyte focuses on the discovery and development of small-molecule drugs. The firms lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incytes other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firms first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incytes pipeline includes a broad array of oncology and dermatology programs. Additional info from NASDAQ: |
2026-05-14 13:47
New Form SCHEDULE 13G/A - INCYTE CORP <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0001193125-26-223367 <b>Size:</b> 7 KB
Read more
2026-05-13 16:52
Incyte anuncia que logró la aceptación de más de 20 resúmenes para su presentación en el Congreso 2026 de la European Hematology Association (EHA)
Read more
2026-05-13 16:52
Incyte rende noto che oltre 20 abstract sono stati accettati per la presentazione al Congresso 2026 della European Hematology Association (EHA)
Read more
2026-05-13 16:52
Incyte maakt bekend dat meer dan 20 abstracts zijn geselecteerd voor presentatie op het congres van de European Hematology Association (EHA) in 2026
Read more
2026-05-13 16:52
Incyte annonce que plus de 20 résumés ont été retenus en vue dune présentation lors du Congrès 2026 de lAssociation européenne dhématologie (EHA)
Read more
2026-05-13 16:51
Incyte gibt bekannt, dass mehr als 20 Abstrakte für die Präsentation auf dem Kongress der European Hematology Association (EHA) 2026 angenommen wurden
Read more
2026-05-12 13:30
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
Read more
2026-05-11 20:45
BAKER BROS. ADVISORS LP 🟡 adjusted position in 0 shares (2 derivative) of INCYTE CORP (INCY) at $84.53 ($5.1M) Transaction Date: May 08, 2026 | Filing ID: 216988
Read more
2026-05-11 18:00
New Form SCHEDULE 13D/A - INCYTE CORP <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0001104659-26-058726 <b>Size:</b> 77 KB
Read more
2026-05-07 23:01
Incyte gibt Langzeitdaten nach 24 Wochen aus der Phase-3-Studie TRuE-AD4 zur Opzelura® (Ruxolitinib)-Creme bei Erwachsenen mit mittelschwerer atopischer Dermatitis bekannt
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03906318 | Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia | — | Aplastic Anemia | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT01730755 | Ruxolitinib for Chuvash Polycythemia | — | Erythrocytosis, Familial, 2 | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03147742 | An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Hos… | — | Graft-versus-host Disease (GVHD) | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT06910137 | An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA0001… | — | Squamous Cell Carcinoma of the Anal Canal | Available | — | — | ClinicalTrials.gov |
| NCT03906357 | Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancre… | — | — | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT05561985 | Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of … | — | STAT1 Gain-of-Function Disease | Available | — | — | ClinicalTrials.gov |
| NCT04355793 | Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine … | — | COVID-19 | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT05544032 | Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Vers… | — | Chronic Graft Vs. Host Disease | Available | — | — | ClinicalTrials.gov |
| NCT05722912 | Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD | — | Graft-versus-host Disease (GVHD) | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT03896815 | Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Ren… | — | — | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03906344 | Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis | — | — | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07511062 | Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutate… | Phase1 | Acute Myeloid Leukemia | Not_Yet_Recruiting | 2026-08-01 | 2030-08-01 | ClinicalTrials.gov |
| NCT07249346 | Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ru… | Phase2 | Leukemia | Recruiting | 2026-06-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT07015853 | ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combi… | Phase2 | TNBC - Triple-Negative Breast Cancer | Not_Yet_Recruiting | 2026-06-01 | 2033-07-01 | ClinicalTrials.gov |
| NCT07424222 | Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocyto… | Phase1 | Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) | Not_Yet_Recruiting | 2026-06-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT06616155 | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resista… | Phase1 | Castration-Resistant Prostate Carcinoma | Recruiting | 2026-06-01 | 2030-06-01 | ClinicalTrials.gov |
| NCT07124078 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Parti… | Phase2 | Chronic Graft-versus-host-disease | Recruiting | 2026-05-31 | 2029-07-31 | ClinicalTrials.gov |
| NCT07548983 | Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acu… | Phase1 | Acute Myeloid Leukemia | Not_Yet_Recruiting | 2026-05-20 | 2028-12-29 | ClinicalTrials.gov |
| NCT07588139 | A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic … | Phase1 | Healthy Participants | Recruiting | 2026-05-18 | 2026-09-19 | ClinicalTrials.gov |
| NCT07559396 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administer… | Phase1 | Renal Impairment | Not_Yet_Recruiting | 2026-05-15 | 2027-01-04 | ClinicalTrials.gov |
| NCT07559474 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administer… | Phase1 | Hepatic Insufficiency | Not_Yet_Recruiting | 2026-05-15 | 2027-04-13 | ClinicalTrials.gov |
| NCT07252050 | Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell D… | Phase1 | Sickle Cell Disease | Recruiting | 2026-05-01 | 2029-11-19 | ClinicalTrials.gov |
| NCT07502872 | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for… | Phase2 | Diffuse Large B Cell Lymphoma | Not_Yet_Recruiting | 2026-05-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT07441694 | Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Phase1 | Myeloproliferative Neoplasms | Recruiting | 2026-04-27 | 2030-05-24 | ClinicalTrials.gov |
| NCT07522073 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untre… | Phase3 | Solid Tumors | Recruiting | 2026-04-09 | 2029-03-19 | ClinicalTrials.gov |
| NCT07434843 | PH 2 Pemigatinib in SDH-deficient GIST | Phase2 | SDH Gene Mutation | Recruiting | 2026-04-01 | 2029-04-01 | ClinicalTrials.gov |
| NCT07448155 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA03398… | Phase1 | Healthy Participants | Active_Not_Recruiting | 2026-03-19 | 2026-05-23 | ClinicalTrials.gov |
| NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy an… | Phase3 | CRC (Colorectal Cancer) | Recruiting | 2026-03-05 | 2029-09-28 | ClinicalTrials.gov |
| NCT07425054 | HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advance… | Phase2 | Anal Cancer | Not_Yet_Recruiting | 2026-03-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT07356245 | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | Phase2 | T-cell Lymphoma | Recruiting | 2026-02-12 | 2027-01-31 | ClinicalTrials.gov |
| NCT07228624 | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Pat… | Phase2 | Myelodysplastic/Myeloproliferative Neoplasm | Recruiting | 2026-02-04 | 2030-09-01 | ClinicalTrials.gov |
| NCT07213973 | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participan… | Phase2 | Hidradenitis Suppurativa (HS) | Recruiting | 2026-02-02 | 2028-03-25 | ClinicalTrials.gov |
| NCT06728410 | A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced … | Phase2 | Intrahepatic Cholangiocarcinoma | Recruiting | 2026-01-27 | 2027-07-01 | ClinicalTrials.gov |
| NCT07359859 | A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With … | Phase2 | Hematologic Malignancies | Recruiting | 2026-01-20 | 2029-01-01 | ClinicalTrials.gov |
| NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and H… | Phase1 | Solid Tumors | Recruiting | 2026-01-08 | 2028-08-18 | ClinicalTrials.gov |
| NCT07219576 | Retifanlimab and Ruxolitinib In Solid Malignancies | Phase1 | Non Small Cell Lung Carcinoma | Recruiting | 2026-01-08 | 2029-12-01 | ClinicalTrials.gov |
| NCT07104565 | Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participant… | Phase2 | Immune Thrombocytopenia | Recruiting | 2025-12-29 | 2028-03-09 | ClinicalTrials.gov |
| NCT07085039 | Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease | Phase2 | Castleman's Disease (CD) | Recruiting | 2025-12-18 | 2028-12-31 | ClinicalTrials.gov |
| NCT07214779 | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Pa… | Phase3 | Ovarian Cancer | Recruiting | 2025-12-09 | 2029-05-14 | ClinicalTrials.gov |
| NCT06991101 | Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolom… | Phase2 | Glioblastoma | Recruiting | 2025-12-03 | 2030-12-01 | ClinicalTrials.gov |
| NCT07283822 | Amping up With PemJAK | Phase2 | Non-Hodgkin Lymphoma | Recruiting | 2025-12-03 | 2029-01-01 | ClinicalTrials.gov |
| NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treat… | Phase1 | Non Hodgkin Lymphoma | Not_Yet_Recruiting | 2025-12-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT06551584 | Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allo… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2025-12-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT06804811 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6… | Phase3 | NonSegmental Vitiligo | Recruiting | 2025-11-13 | 2027-12-01 | ClinicalTrials.gov |
| NCT07218744 | Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of … | Phase1 | Healthy Participants | Completed | 2025-11-13 | 2025-12-10 | ClinicalTrials.gov |
| NCT07023627 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer Wi… | Phase2 | Ovarian Cancer | Recruiting | 2025-11-12 | 2027-10-24 | ClinicalTrials.gov |
| NCT07049575 | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent … | Phase1 | Hidradenitis Suppurativa | Recruiting | 2025-11-03 | 2026-12-09 | ClinicalTrials.gov |
| NCT06233110 | Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD | Phase1 | Chronic Graft Versus Host Disease | Recruiting | 2025-10-29 | 2029-07-01 | ClinicalTrials.gov |
| NCT06300528 | Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas | Phase2 | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | 2025-10-03 | 2030-12-01 | ClinicalTrials.gov |
| NCT07008118 | A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Phase1 | Myeloproliferative Neoplasms | Recruiting | 2025-10-01 | 2029-12-14 | ClinicalTrials.gov |
| NCT06752694 | Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoie… | Phase2 | Aplastic Anemia | Recruiting | 2025-09-25 | 2027-12-31 | ClinicalTrials.gov |
| NCT06896188 | 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With… | Phase1 | Pancreatic Adenocarcinoma | Recruiting | 2025-09-22 | 2028-12-31 | ClinicalTrials.gov |
| NCT06906562 | A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib i… | Phase2 | Advanced Pancreatic Carcinoma | Recruiting | 2025-08-26 | 2028-12-31 | ClinicalTrials.gov |
| NCT07030699 | A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse… | Phase2 | Lymphoma | Withdrawn | 2025-08-13 | 2026-03-31 | ClinicalTrials.gov |
| NCT06792825 | HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-na… | Phase2 | Follicular Lymphoma | Recruiting | 2025-08-07 | 2031-07-08 | ClinicalTrials.gov |
| NCT07011810 | Axatilimab for Sclerotic Chronic Graft-versus-Host Disease | Phase2 | Chronic Graft Versus Host Disease | Recruiting | 2025-08-06 | 2030-02-10 | ClinicalTrials.gov |
| NCT07126236 | Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Effica… | Phase2 | Large B Cell Lymphoma | Recruiting | 2025-08-04 | 2031-12-01 | ClinicalTrials.gov |
| NCT07039929 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 Wh… | Phase1 | Healthy Participants | Terminated | 2025-07-28 | 2025-10-11 | ClinicalTrials.gov |
| NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft… | Phase2 | AML (Acute Myelogenous Leukemia) | Recruiting | 2025-07-25 | 2028-06-01 | ClinicalTrials.gov |
| NCT07018635 | A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agent… | Phase1 | Healthy Participants | Completed | 2025-07-16 | 2025-09-29 | ClinicalTrials.gov |
| NCT06873789 | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastat… | Phase1 | Solid Tumors | Active_Not_Recruiting | 2025-06-30 | 2026-05-08 | ClinicalTrials.gov |
| NCT06934980 | A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fl… | — | Atopic Dermatitis | Completed | 2025-06-27 | 2025-12-19 | ClinicalTrials.gov |
| NCT06843408 | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent… | Phase1 | Chronic Graft-versus-host-disease | Recruiting | 2025-06-25 | 2027-12-31 | ClinicalTrials.gov |
| NCT06959225 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants … | Phase3 | Hidradenitis Suppurativa | Recruiting | 2025-06-23 | 2027-07-11 | ClinicalTrials.gov |
| NCT06832618 | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and … | Phase3 | Atopic Dermatitis | Recruiting | 2025-06-17 | 2028-05-18 | ClinicalTrials.gov |
| NCT06958211 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants … | Phase3 | Hidradenitis Suppurativa | Recruiting | 2025-06-12 | 2027-07-11 | ClinicalTrials.gov |
| NCT06821542 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants Wi… | Phase3 | Chronic Graft-versus-host-disease | Active_Not_Recruiting | 2025-06-04 | 2032-11-30 | ClinicalTrials.gov |
| NCT06936566 | MAGIC Ruxolitinib for aGVHD | Phase2 | Acute Graft-versus-host Disease | Recruiting | 2025-05-14 | 2028-04-14 | ClinicalTrials.gov |
| NCT06941077 | A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057… | Phase1 | Healthy Volunteers | Completed | 2025-05-12 | 2025-06-03 | ClinicalTrials.gov |
| NCT06663722 | Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Gr… | Phase2 | Chronic Graft Versus Host Disease | Recruiting | 2025-05-05 | 2030-05-05 | ClinicalTrials.gov |
| NCT06909162 | A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and … | Phase1 | Healthy Participants | Recruiting | 2025-05-05 | 2026-05-17 | ClinicalTrials.gov |
| NCT06610682 | A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanl… | Early_Phase1 | BRAF V600E Mutation | Recruiting | 2025-04-07 | 2028-06-30 | ClinicalTrials.gov |
| NCT06615050 | A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophos… | Phase3 | Graft-versus-host Disease (GVHD) | Recruiting | 2025-04-02 | 2031-01-17 | ClinicalTrials.gov |
| NCT06818812 | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Soli… | Phase1 | Solid Tumors | Active_Not_Recruiting | 2025-03-27 | 2027-03-27 | ClinicalTrials.gov |
| NCT06760156 | Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell… | Phase2 | Large B-cell Lymphoma | Recruiting | 2025-03-19 | 2028-01-01 | ClinicalTrials.gov |
| NCT06855498 | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povor… | Phase3 | Hidradenitis Suppurativa (HS) | Recruiting | 2025-02-28 | 2028-02-28 | ClinicalTrials.gov |
| NCT06775327 | Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Foo… | Phase1 | Healthy Participants | Completed | 2025-02-13 | 2025-05-28 | ClinicalTrials.gov |
| NCT06548360 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric P… | Phase3 | NonSegmental Vitiligo | Recruiting | 2025-01-24 | 2027-03-13 | ClinicalTrials.gov |
| NCT06585774 | A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chr… | Phase3 | Chronic Graft-versus-host-disease | Recruiting | 2025-01-21 | 2030-03-31 | ClinicalTrials.gov |
| NCT06713590 | A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intrave… | Phase1 | Healthy Participants | Completed | 2025-01-14 | 2025-06-10 | ClinicalTrials.gov |
| NCT06773195 | A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibr… | Phase1 | Myelofibrosis | Recruiting | 2025-01-07 | 2028-01-01 | ClinicalTrials.gov |
| NCT06660355 | Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Ther… | Phase2 | Chronic Graft-versus-host Disease (cGVHD) | Recruiting | 2024-12-23 | 2028-12-01 | ClinicalTrials.gov |
| NCT06649201 | Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation | — | Graft Vs Host Disease | Recruiting | 2024-12-19 | 2027-02-15 | ClinicalTrials.gov |
| NCT06439485 | Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizuma… | Phase1 | Advanced Cholangiocarcinoma | Recruiting | 2024-11-19 | 2030-02-22 | ClinicalTrials.gov |
| NCT06388564 | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With R… | Phase2 | Chronic Graft-versus-host-disease | Recruiting | 2024-10-11 | 2029-12-01 | ClinicalTrials.gov |
| NCT06516952 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participan… | Phase3 | Prurigo Nodularis | Recruiting | 2024-10-10 | 2027-05-03 | ClinicalTrials.gov |
| NCT06516965 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participan… | Phase3 | Prurigo Nodularis | Active_Not_Recruiting | 2024-10-10 | 2027-05-03 | ClinicalTrials.gov |
| NCT06399029 | Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities | Phase2 | Exanthema | Active_Not_Recruiting | 2024-10-10 | 2026-05-01 | ClinicalTrials.gov |
| NCT06345495 | High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis… | Phase2 | Splenomegaly | Recruiting | 2024-10-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT06160791 | Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymp… | Phase2 | Hemophagocytic Lymphohistiocytoses | Recruiting | 2024-10-01 | 2029-11-30 | ClinicalTrials.gov |
| NCT06555081 | A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tab… | Phase1 | Healthy Participants | Completed | 2024-09-25 | 2024-11-07 | ClinicalTrials.gov |
| NCT05583071 | Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | Phase2 | Non-Hodgkin Lymphoma | Recruiting | 2024-08-23 | 2027-04-01 | ClinicalTrials.gov |
| NCT06488378 | Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2-… | Phase1 | Breast Cancer | Recruiting | 2024-08-13 | 2029-03-01 | ClinicalTrials.gov |
| NCT06505265 | A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorc… | Phase1 | Healthy Participants | Completed | 2024-08-12 | 2024-09-18 | ClinicalTrials.gov |
| NCT06313593 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With… | Phase1 | Myeloproliferative Neoplasms | Recruiting | 2024-08-08 | 2028-10-09 | ClinicalTrials.gov |
| NCT06523556 | Axatilimab With or Without Azacitidine for the Treatment of Patients With Advan… | Phase1 | Atypical Chronic Myeloid Leukemia | Recruiting | 2024-08-02 | 2028-10-31 | ClinicalTrials.gov |
| NCT06441318 | A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Health… | Phase1 | Healthy Participants | Completed | 2024-07-12 | 2024-09-10 | ClinicalTrials.gov |
| NCT06416800 | A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metf… | Phase1 | Healthy Participants | Completed | 2024-06-19 | 2025-01-15 | ClinicalTrials.gov |
| NCT06320405 | Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of… | Phase1 | Advanced Malignant Solid Neoplasm | Recruiting | 2024-05-21 | 2029-04-01 | ClinicalTrials.gov |
| NCT06309394 | A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles o… | Phase1 | Healthy Participants | Completed | 2024-05-15 | 2024-06-04 | ClinicalTrials.gov |
| NCT06008808 | Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-V… | Phase1 | Graft Vs Host Disease | Recruiting | 2024-05-07 | 2027-11-27 | ClinicalTrials.gov |
| NCT06380205 | A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Cont… | Phase1 | Healthy Participants | Completed | 2024-05-07 | 2024-06-07 | ClinicalTrials.gov |
| NCT06029309 | Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma | Phase1 | Mantle Cell Lymphoma | Recruiting | 2024-05-03 | 2032-05-01 | ClinicalTrials.gov |
| NCT06337162 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) | Phase1 | Hepatocellular Carcinoma | Withdrawn | 2024-05-01 | 2028-09-01 | ClinicalTrials.gov |
| NCT06238817 | A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adul… | Phase3 | Atopic Dermatitis | Completed | 2024-04-26 | 2025-10-17 | ClinicalTrials.gov |
| NCT06302621 | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | Phase1 | Advanced Solid Tumor | Recruiting | 2024-04-17 | 2027-12-01 | ClinicalTrials.gov |
| NCT05949632 | A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Soli… | Phase1 | Advanced Solid Tumors | Terminated | 2024-04-16 | 2025-06-06 | ClinicalTrials.gov |
| NCT06310304 | A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Releas… | Phase1 | Healthy Participants | Completed | 2024-03-26 | 2024-05-15 | ClinicalTrials.gov |
| NCT06213818 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB16005… | Phase1 | Healthy Participants | Completed | 2024-03-14 | 2025-08-19 | ClinicalTrials.gov |
| NCT06213831 | A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream | Phase1 | Prurigo Nodularis | Completed | 2024-02-27 | 2025-07-17 | ClinicalTrials.gov |
| NCT06212999 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Partic… | Phase3 | Hidradenitis Suppurativa (HS) | Active_Not_Recruiting | 2024-01-30 | 2026-12-26 | ClinicalTrials.gov |
| NCT06179160 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Soli… | Phase1 | Solid Tumors | Recruiting | 2024-01-04 | 2027-01-01 | ClinicalTrials.gov |
| NCT06039384 | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Sol… | Phase1 | Advanced Solid Tumors | Terminated | 2023-12-28 | 2025-07-11 | ClinicalTrials.gov |
| NCT06034002 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination … | Phase1 | Myeloproliferative Neoplasms | Recruiting | 2023-12-04 | 2028-10-29 | ClinicalTrials.gov |
| NCT06113445 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With No… | Phase3 | NonSegmental Vitiligo | Active_Not_Recruiting | 2023-11-29 | 2027-02-24 | ClinicalTrials.gov |
| NCT06113471 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With No… | Phase3 | NonSegmental Vitiligo | Active_Not_Recruiting | 2023-11-27 | 2027-03-16 | ClinicalTrials.gov |
| NCT05491226 | Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibiti… | Phase2 | TNBC - Triple-Negative Breast Cancer | Recruiting | 2023-11-17 | 2026-12-01 | ClinicalTrials.gov |
| NCT06056895 | Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refracto… | Phase2 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 | Active_Not_Recruiting | 2023-11-08 | 2027-04-30 | ClinicalTrials.gov |
| NCT05879822 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are… | Phase2 | Advanced Solid Tumor | Active_Not_Recruiting | 2023-10-30 | 2026-07-22 | ClinicalTrials.gov |
| NCT05743595 | Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Thera… | Phase1 | Unmethylated Glioblastoma | Active_Not_Recruiting | 2023-10-27 | 2029-03-09 | ClinicalTrials.gov |
| NCT05888844 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous… | Phase2 | Cutaneous Squamous Cell Carcinoma | Active_Not_Recruiting | 2023-10-09 | 2026-09-28 | ClinicalTrials.gov |
| NCT05943496 | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Un… | Phase1 | Chronic Lymphocytic Leukemia | Recruiting | 2023-10-02 | 2028-01-01 | ClinicalTrials.gov |
| NCT05890352 | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned o… | Phase2 | Grade 3b Follicular Lymphoma | Recruiting | 2023-09-26 | 2029-01-01 | ClinicalTrials.gov |
| NCT05936359 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination … | Phase1 | Myeloproliferative Neoplasms | Recruiting | 2023-09-25 | 2028-02-29 | ClinicalTrials.gov |
| NCT06259669 | Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Mod… | — | Pregnancy Related | Recruiting | 2023-09-13 | 2033-08-01 | ClinicalTrials.gov |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select … | Phase1 | Melanoma | Terminated | 2023-08-29 | 2024-11-11 | ClinicalTrials.gov |
| NCT05626322 | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People W… | Phase1 | Diffuse Large B-Cell Lymphoma | Terminated | 2023-08-04 | 2025-05-01 | ClinicalTrials.gov |
| NCT05919511 | Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease | — | cGVHD | Recruiting | 2023-08-01 | 2027-10-15 | ClinicalTrials.gov |
| NCT05936567 | Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic… | Phase2 | Urticaria | Completed | 2023-07-31 | 2025-10-09 | ClinicalTrials.gov |
| NCT05906628 | Topical Ruxolitinib Evaluation in Chronic Hand Eczema | Phase2 | Hand Eczema | Completed | 2023-07-31 | 2024-12-13 | ClinicalTrials.gov |
| NCT05943964 | Virtual Rehabilitation in HCT | Na | Hematopoietic Cell Transplant | Recruiting | 2023-07-31 | 2027-08-01 | ClinicalTrials.gov |
| NCT05836324 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Me… | Phase1 | Solid Tumors | Recruiting | 2023-07-24 | 2027-01-13 | ClinicalTrials.gov |
| NCT05851443 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participan… | Phase2 | Moderate to Severe Asthma | Recruiting | 2023-07-11 | 2027-01-31 | ClinicalTrials.gov |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | Phase1 | Leukemia, Acute | Active_Not_Recruiting | 2023-07-06 | 2030-03-01 | ClinicalTrials.gov |
| NCT05764161 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participant… | Phase3 | Prurigo Nodularis | Completed | 2023-06-12 | 2025-11-04 | ClinicalTrials.gov |
| NCT05757219 | Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | Phase2 | Diffuse Large B Cell Lymphoma | Recruiting | 2023-05-19 | 2027-01-01 | ClinicalTrials.gov |
| NCT05723055 | Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Re… | Phase2 | Hodgkin Lymphoma | Active_Not_Recruiting | 2023-05-03 | 2028-04-01 | ClinicalTrials.gov |
| NCT04799431 | Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With … | Phase1 | Pancreatic Cancer Metastatic | Withdrawn | 2023-05-03 | 2023-05-03 | ClinicalTrials.gov |
| NCT05750823 | A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants … | Phase2 | Nonsegmental Vitiligo With Genital Involvement | Completed | 2023-04-11 | 2025-03-06 | ClinicalTrials.gov |
| NCT05453500 | Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatmen… | Phase2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Active_Not_Recruiting | 2023-03-27 | 2031-05-01 | ClinicalTrials.gov |
| NCT06627335 | An Observational Retrospective Cohort Study Being Conducted in Women With Atopi… | — | Pregnancy Related | Recruiting | 2023-03-27 | 2028-08-15 | ClinicalTrials.gov |
| NCT05696392 | The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Ad… | Phase4 | Atopic Dermatitis | Terminated | 2023-03-16 | 2025-01-22 | ClinicalTrials.gov |
| NCT05788289 | A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma | Phase2 | Mantle Cell Lymphoma | Terminated | 2023-03-14 | 2024-08-01 | ClinicalTrials.gov |
| NCT05755438 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participant… | Phase3 | Prurigo | Completed | 2023-03-10 | 2025-08-13 | ClinicalTrials.gov |
| NCT05660421 | Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events A… | Phase2 | Hematopoietic and Lymphoid Cell Neoplasm | Withdrawn | 2023-03-03 | 2025-04-03 | ClinicalTrials.gov |
| NCT05620836 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Par… | Phase3 | Hidradenitis Suppurativa (HS) | Completed | 2023-02-22 | 2025-11-21 | ClinicalTrials.gov |
| NCT05233410 | Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 | Phase3 | Chronic Hand Eczema (CHE) | Withdrawn | 2023-01-31 | 2024-09-22 | ClinicalTrials.gov |
| NCT05219864 | Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 | Phase3 | Hand Eczema | Withdrawn | 2023-01-31 | 2024-09-22 | ClinicalTrials.gov |
| NCT05714072 | A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Mye… | Phase1 | Myelofibrosis Due to and Following Polycythemia Vera | Recruiting | 2023-01-25 | 2027-01-01 | ClinicalTrials.gov |
| NCT05440942 | Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenoca… | Phase1 | Pancreatic Ductal Adenocarcinoma | Completed | 2023-01-19 | 2025-05-30 | ClinicalTrials.gov |
| NCT05624723 | Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054… | Phase1 | Renal Insufficiency | Completed | 2023-01-12 | 2024-02-07 | ClinicalTrials.gov |
| NCT05577182 | Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Se… | Phase1 | Advanced Malignancies | Completed | 2023-01-05 | 2025-10-13 | ClinicalTrials.gov |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutu… | Phase3 | Follicular Lymphoma ( FL) | Withdrawn | 2022-12-30 | 2032-08-25 | ClinicalTrials.gov |
| NCT05429268 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in P… | Phase3 | Large B-Cell Lymphoma | Active_Not_Recruiting | 2022-12-23 | 2027-04-01 | ClinicalTrials.gov |
| NCT05620823 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Par… | Phase3 | Hidradenitis Suppurativa (HS) | Completed | 2022-12-19 | 2025-12-23 | ClinicalTrials.gov |
| NCT06209606 | Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Mul… | Early_Phase1 | Multiple Myeloma | Recruiting | 2022-12-08 | 2029-02-01 | ClinicalTrials.gov |
| NCT05624710 | A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participan… | Phase1 | Renal Insufficiency | Completed | 2022-12-08 | 2023-06-30 | ClinicalTrials.gov |
| NCT05635838 | Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participan… | Phase2 | Hidradenitis Suppurativa | Completed | 2022-12-07 | 2024-03-14 | ClinicalTrials.gov |
| NCT05593432 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participant… | Phase2 | Cutaneous Lichen Planus | Completed | 2022-11-23 | 2024-02-26 | ClinicalTrials.gov |
| NCT05593445 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participant… | Phase2 | Lichen Sclerosus | Completed | 2022-11-18 | 2023-12-21 | ClinicalTrials.gov |
| NCT05345002 | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Gli… | Phase2 | Glioma | Recruiting | 2022-11-16 | 2028-06-01 | ClinicalTrials.gov |
| NCT05787860 | Ruxolitinib in Seborrheic Dermatitis | Phase2 | Seborrheic Dermatitis | Completed | 2022-11-15 | 2024-01-26 | ClinicalTrials.gov |
| NCT06465433 | Extension Study to Provide Continued Treatment for Patients With Hematologic Ma… | Phase2 | Hematologic Malignancies | Recruiting | 2022-11-08 | 2027-08-29 | ClinicalTrials.gov |
| NCT04414514 | Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment | Phase2 | Hidradenitis Suppurativa | Terminated | 2022-10-13 | 2024-02-23 | ClinicalTrials.gov |
| NCT05456529 | Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis | Phase3 | Atopic Dermatitis (AD) | Completed | 2022-09-01 | 2024-05-17 | ClinicalTrials.gov |
| NCT05083754 | Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Te… | Phase1 | Glioblastoma Multiforme | Recruiting | 2022-08-31 | 2029-01-01 | ClinicalTrials.gov |
| NCT05222555 | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen C… | Phase1 | Diffuse Large B Cell Lymphoma | Active_Not_Recruiting | 2022-07-19 | 2027-11-30 | ClinicalTrials.gov |
| NCT05293717 | Topical Ruxolitinib in Chronic Hand Dermatitis | Phase1 | Chronic Hand Dermatitis | Completed | 2022-07-11 | 2024-12-31 | ClinicalTrials.gov |
| NCT05238922 | Study of INCB123667 in Subjects With Advanced Solid Tumors | Phase1 | Solid Tumors | Recruiting | 2022-07-05 | 2027-08-31 | ClinicalTrials.gov |
| NCT05298293 | Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma | Na | Diffuse Large B Cell Lymphoma | Not_Yet_Recruiting | 2022-07-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT05216120 | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | Phase2 | Pancreas Cancer | Withdrawn | 2022-06-14 | 2025-08-31 | ClinicalTrials.gov |
| NCT05351593 | Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | Phase1 | CNS Lymphoma | Recruiting | 2022-06-08 | 2026-06-30 | ClinicalTrials.gov |
| NCT05267106 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With P… | Phase2 | Glioblastoma | Terminated | 2022-05-20 | 2024-12-17 | ClinicalTrials.gov |
| NCT05247489 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Photother… | Phase2 | Vitiligo | Completed | 2022-05-05 | 2023-12-19 | ClinicalTrials.gov |
| NCT05090891 | To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants … | Phase2 | Fibrodysplasia Ossificans Progressiva (FOP) | Recruiting | 2022-05-05 | 2033-01-20 | ClinicalTrials.gov |
| NCT04908280 | Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus | Phase2 | Discoid Lupus Erythematosus | Completed | 2022-05-04 | 2024-03-04 | ClinicalTrials.gov |
| NCT05063110 | Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB | Phase2 | Adults Patients Having Non Severe HLH | Completed | 2022-05-03 | 2025-10-01 | ClinicalTrials.gov |
| NCT05253807 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With R… | Phase2 | Non-Small Cell Lung Cancer (NSCLC) | Completed | 2022-04-29 | 2023-08-16 | ClinicalTrials.gov |
| NCT04807777 | Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneo… | Phase2 | Advanced Cutaneous Squamous Cell Carcinoma | Terminated | 2022-04-07 | 2023-10-04 | ClinicalTrials.gov |
| NCT04644211 | Ruxolitinib in Thrombocythemia and Polycythemia Vera | Phase2 | Essential Thrombocythemia | Recruiting | 2022-03-21 | 2034-07-01 | ClinicalTrials.gov |
| NCT05073458 | Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Wa… | Phase3 | Warm Autoimmune Hemolytic Anemia (wAIHA) | Terminated | 2022-03-15 | 2024-04-29 | ClinicalTrials.gov |
| NCT04849715 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and… | Phase3 | Mantle Cell Lymphoma | Withdrawn | 2022-03-11 | 2034-07-07 | ClinicalTrials.gov |
| NCT04906746 | Ruxolitinib for Cancer Cachexia | Early_Phase1 | Stage IV Non-small Cell Lung Cancer | Active_Not_Recruiting | 2022-02-23 | 2025-12-01 | ClinicalTrials.gov |
| NCT05239182 | 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Adva… | Phase2 | Pancreatic Adenocarcinoma | Terminated | 2022-01-26 | 2024-02-04 | ClinicalTrials.gov |
| NCT05101369 | A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles o… | Phase1 | Healthy Volunteers | Completed | 2022-01-21 | 2022-03-25 | ClinicalTrials.gov |
| NCT04586244 | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy o… | Phase2 | Urothelial Carcinoma | Terminated | 2022-01-14 | 2024-01-29 | ClinicalTrials.gov |
| NCT04859946 | Itacitinib for the Prevention of Graft Versus Host Disease | Phase2 | Hematologic and Lymphocytic Disorder | Active_Not_Recruiting | 2022-01-11 | 2027-04-01 | ClinicalTrials.gov |
| NCT05034822 | Study of Ruxolitinib Cream in Children With Atopic Dermatitis | Phase1 | Atopic Dermatitis | Completed | 2021-12-16 | 2023-08-07 | ClinicalTrials.gov |
| NCT05099445 | Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000… | Phase1 | Renal Impairment | Completed | 2021-12-14 | 2023-02-27 | ClinicalTrials.gov |
| NCT04061421 | Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overla… | Phase1 | MDS/MPN | Recruiting | 2021-11-24 | 2027-12-01 | ClinicalTrials.gov |
| NCT05127421 | Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Inv… | Phase2 | Atopic Dermatitis | Completed | 2021-11-10 | 2023-09-29 | ClinicalTrials.gov |
| NCT05177133 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer… | Phase2 | Gastric Adenocarcinoma | Recruiting | 2021-11-05 | 2029-11-04 | ClinicalTrials.gov |
| NCT05061693 | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With … | Phase2 | Prurigo Nodularis | Completed | 2021-11-04 | 2024-02-28 | ClinicalTrials.gov |
| NCT04839380 | The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch… | Phase2 | Atopic Dermatitis | Completed | 2021-10-12 | 2022-11-18 | ClinicalTrials.gov |
| NCT04989387 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Terminated | 2021-10-04 | 2024-09-19 | ClinicalTrials.gov |
| NCT04981795 | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Com… | — | Diffuse Large B-cell Lymphoma | Completed | 2021-09-20 | 2026-01-23 | ClinicalTrials.gov |
| NCT04809467 | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in P… | Phase1 | Chronic Lymphocytic Leukemia | Terminated | 2021-09-16 | 2024-10-22 | ClinicalTrials.gov |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | Phase2 | Non Small Cell Lung Cancer | Terminated | 2021-09-02 | 2024-03-26 | ClinicalTrials.gov |
| NCT04582539 | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelod… | Phase1 | Myelodysplastic Syndromes | Terminated | 2021-08-19 | 2024-08-15 | ClinicalTrials.gov |
| NCT04921969 | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With… | Phase3 | Atopic Dermatitis | Completed | 2021-07-19 | 2024-04-08 | ClinicalTrials.gov |
| NCT04551131 | Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of H… | Phase1 | Hemophagocytic Lymphohistiocytosis | Active_Not_Recruiting | 2021-07-13 | 2026-08-01 | ClinicalTrials.gov |
| NCT04629508 | To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release… | Phase2 | Myelofibrosis | Completed | 2021-07-12 | 2023-08-24 | ClinicalTrials.gov |
| NCT04949191 | The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With… | Phase2 | Advanced Malignancies | Terminated | 2021-07-08 | 2024-04-11 | ClinicalTrials.gov |
| NCT04896385 | A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects Wi… | Phase2 | Vitiligo | Completed | 2021-06-23 | 2023-07-10 | ClinicalTrials.gov |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants … | Phase3 | Myelofibrosis | Terminated | 2021-05-26 | 2024-08-21 | ClinicalTrials.gov |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participa… | Phase3 | Myelofibrosis | Terminated | 2021-05-24 | 2024-11-25 | ClinicalTrials.gov |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-inter… | Phase3 | Diffuse Large B-cell Lymphoma | Active_Not_Recruiting | 2021-05-11 | 2027-11-01 | ClinicalTrials.gov |
| NCT04818346 | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With … | Phase2 | NonSegmental Vitiligo | Completed | 2021-05-06 | 2023-05-24 | ClinicalTrials.gov |
| NCT04831996 | To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants Wi… | Phase1 | Advanced Malignancies | Completed | 2021-05-04 | 2022-07-08 | ClinicalTrials.gov |
| NCT04680052 | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide … | Phase3 | Follicular Lymphoma | Active_Not_Recruiting | 2021-04-15 | 2028-08-09 | ClinicalTrials.gov |
| NCT04831944 | To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants Wi… | Phase1 | Advanced Malignancies | Completed | 2021-03-29 | 2022-03-11 | ClinicalTrials.gov |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in P… | Phase1 | Advanced Solid Tumors | Terminated | 2021-03-26 | 2024-08-16 | ClinicalTrials.gov |
| NCT04455841 | INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in … | Phase1 | Anemia | Active_Not_Recruiting | 2021-03-19 | 2027-11-26 | ClinicalTrials.gov |
| NCT04640025 | A Rollover Study to Provide Continued Treatment for Participants Previously Enr… | Phase2 | Myelofibrosis | Active_Not_Recruiting | 2021-03-10 | 2026-06-22 | ClinicalTrials.gov |
| NCT04279847 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis … | Phase1 | Myelofibrosis | Active_Not_Recruiting | 2021-02-23 | 2027-04-30 | ClinicalTrials.gov |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | Phase1 | Ovarian Cancer | Completed | 2021-02-03 | 2024-01-22 | ClinicalTrials.gov |
| NCT04446182 | Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line T… | Phase2 | Chronic Graft-versus-host-disease | Terminated | 2021-01-29 | 2023-01-30 | ClinicalTrials.gov |
| NCT04463771 | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With … | Phase2 | Endometrial Cancer | Active_Not_Recruiting | 2021-01-26 | 2026-07-10 | ClinicalTrials.gov |
| NCT04281498 | Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase My… | Phase2 | Accelerated/Blast-phase Myeloproliferative Neoplasm | Completed | 2021-01-14 | 2023-05-30 | ClinicalTrials.gov |
| NCT04659616 | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myelo… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2021-01-14 | 2026-12-31 | ClinicalTrials.gov |
| NCT04472429 | Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locall… | Phase3 | Squamous Cell Carcinoma of the Anal Canal | Completed | 2021-01-12 | 2025-09-26 | ClinicalTrials.gov |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metasta… | Phase2 | Epstein-Barr Virus Positive | Withdrawn | 2020-12-01 | 2024-04-01 | ClinicalTrials.gov |
| NCT03914794 | A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recu… | Phase2 | Bladder Cancer | Completed | 2020-10-02 | 2025-09-30 | ClinicalTrials.gov |
| NCT04577014 | Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients Wi… | Phase1 | Soft Tissue Sarcoma | Recruiting | 2020-09-29 | 2026-09-29 | ClinicalTrials.gov |
| NCT04530344 | Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants W… | Phase3 | Vitiligo | Completed | 2020-09-24 | 2022-11-14 | ClinicalTrials.gov |
| NCT04205812 | Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in… | Phase3 | Metastatic Squamous Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2020-09-11 | 2026-08-28 | ClinicalTrials.gov |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in P… | Phase1 | Advanced Solid Tumor | Completed | 2020-09-04 | 2024-11-21 | ClinicalTrials.gov |
| NCT04476043 | To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenit… | Phase2 | Hidradenitis Suppurativa | Completed | 2020-08-25 | 2023-08-16 | ClinicalTrials.gov |
| NCT04509700 | Rollover Study to Provide Continued Treatment for Participants With B-Cell Mali… | Phase2 | B-Cell Malignancies | Active_Not_Recruiting | 2020-08-03 | 2027-09-30 | ClinicalTrials.gov |
| NCT04203511 | INCMGA00012 in Combination With Chemoradiation in Participants With Stage III N… | Phase3 | Non-small Cell Lung Cancer | Withdrawn | 2020-07-31 | 2025-01-31 | ClinicalTrials.gov |
| NCT04370704 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LA… | Phase1 | Melanoma | Completed | 2020-07-27 | 2025-08-25 | ClinicalTrials.gov |
| NCT04445844 | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Brea… | Phase2 | Anatomic Stage IV Breast Cancer AJCC v8 | Active_Not_Recruiting | 2020-07-13 | 2025-06-30 | ClinicalTrials.gov |
| NCT04354714 | Ruxolitinib to Combat COVID-19 | Phase2 | COVID-19 | Withdrawn | 2020-06-30 | 2021-12-31 | ClinicalTrials.gov |
| NCT04225039 | Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | Phase2 | Glioblastoma | Active_Not_Recruiting | 2020-06-23 | 2029-04-30 | ClinicalTrials.gov |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Rela… | Phase2 | Neurofibromatosis Type 2 | Recruiting | 2020-06-20 | 2030-12-01 | ClinicalTrials.gov |
| NCT04438824 | Palbociclib and INCMGA00012 in People With Advanced Liposarcoma | Phase2 | Well-differentiated/Dedifferentiated Liposarcoma | Active_Not_Recruiting | 2020-06-17 | 2026-06-01 | ClinicalTrials.gov |
| NCT04200365 | A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (c… | Phase2 | Chronic Graft-versus-host-disease | Terminated | 2020-06-05 | 2023-09-07 | ClinicalTrials.gov |
| NCT04142554 | Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Can… | Phase1 | Breast Cancer | Withdrawn | 2020-06-01 | 2020-09-07 | ClinicalTrials.gov |
| NCT04377620 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-… | Phase3 | COVID-19 | Terminated | 2020-05-24 | 2021-02-26 | ClinicalTrials.gov |
| NCT04003610 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothe… | Phase2 | Metastatic Urothelial Carcinoma | Terminated | 2020-05-14 | 2021-04-18 | ClinicalTrials.gov |
| NCT04362137 | Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-1… | Phase3 | Cytokine Storm (Covid-19) | Completed | 2020-05-02 | 2020-10-17 | ClinicalTrials.gov |
| NCT03532295 | Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in P… | Phase2 | Glioma | Completed | 2020-04-20 | 2025-10-31 | ClinicalTrials.gov |
| NCT04116073 | INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Aden… | Phase2 | Pancreatic Cancer Non-resectable | Completed | 2020-04-09 | 2024-12-03 | ClinicalTrials.gov |
| NCT04055844 | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in… | Phase2 | Acute Myeloid Leukemia | Completed | 2020-02-17 | 2022-09-06 | ClinicalTrials.gov |
| NCT04086745 | A Study of Baricitinib in Participants With Rheumatoid Arthritis | Phase4 | Rheumatoid Arthritis | Completed | 2020-02-14 | 2025-05-19 | ClinicalTrials.gov |
| NCT04071366 | A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced b… | Phase2 | Cytokine Release Syndrome | Completed | 2020-02-07 | 2023-08-22 | ClinicalTrials.gov |
| NCT03978637 | Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans… | Phase1 | Bronchiolitis Obliterans Syndrome | Terminated | 2020-02-04 | 2023-10-13 | ClinicalTrials.gov |
| NCT04070781 | Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disea… | Phase1 | Steroid Refractory GVHD | Terminated | 2020-01-20 | 2021-12-13 | ClinicalTrials.gov |
| NCT03516708 | Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With … | Phase1 | Rectal Cancer | Recruiting | 2020-01-06 | 2030-08-12 | ClinicalTrials.gov |
| NCT03721965 | Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treat… | Phase1 | Acute Graft-versus-host Disease | Terminated | 2019-12-31 | 2020-02-17 | ClinicalTrials.gov |
| NCT03610971 | Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosi… | Phase2 | Chronic Phase Chronic Myeloid Leukemia | Active_Not_Recruiting | 2019-11-19 | 2026-10-01 | ClinicalTrials.gov |
| NCT03801434 | Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eos… | Phase2 | BCR-JAK2 Fusion Protein Expression | Recruiting | 2019-11-15 | 2028-12-30 | ClinicalTrials.gov |
| NCT04003623 | Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR … | Phase2 | Advanced or Metastatic Solid Tumors | Terminated | 2019-10-31 | 2020-06-12 | ClinicalTrials.gov |
| NCT03822117 | Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metas… | Phase2 | Solid Tumor Malignancy | Terminated | 2019-10-17 | 2022-03-29 | ClinicalTrials.gov |
| NCT04057573 | Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) | Phase3 | Non-segmental Vitiligo | Completed | 2019-10-03 | 2021-10-01 | ClinicalTrials.gov |
| NCT03670069 | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | Phase1 | Metastatic Leiomyosarcoma | Terminated | 2019-09-30 | 2024-05-06 | ClinicalTrials.gov |
| NCT03837509 | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab… | Phase1 | Relapsed or Refractory Multiple Myeloma | Terminated | 2019-09-25 | 2022-04-05 | ClinicalTrials.gov |
| NCT04052425 | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) | Phase3 | Non-segmental Vitiligo | Completed | 2019-09-20 | 2021-10-21 | ClinicalTrials.gov |
| NCT03843125 | A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) | Phase3 | Systemic Lupus Erythematosus | Terminated | 2019-09-09 | 2022-04-01 | ClinicalTrials.gov |
| NCT03755414 | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytoki… | Phase1 | Acute Myelogenous Leukemia | Completed | 2019-09-04 | 2024-05-26 | ClinicalTrials.gov |
| NCT03722407 | Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phas… | Phase2 | Chronic Myelomonocytic Leukemia | Active_Not_Recruiting | 2019-08-28 | 2026-06-01 | ClinicalTrials.gov |
| NCT03874052 | Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Trea… | Phase1 | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recruiting | 2019-08-16 | 2027-12-31 | ClinicalTrials.gov |
| NCT03920839 | INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1U… | Phase1 | Advanced and/or Metastatic Solid Tumors | Withdrawn | 2019-07-15 | 2019-11-04 | ClinicalTrials.gov |
| NCT03899259 | A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopeci… | Phase3 | Alopecia Areata | Completed | 2019-07-08 | 2024-11-19 | ClinicalTrials.gov |
| NCT03471286 | A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel The… | Phase1 | Solid Tumor | Terminated | 2019-06-06 | 2021-07-30 | ClinicalTrials.gov |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy … | Phase3 | Unresectable Cholangiocarcinoma | Terminated | 2019-06-03 | 2025-07-07 | ClinicalTrials.gov |
| NCT03920852 | A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants W… | Phase1 | Atopic Dermatitis | Completed | 2019-05-30 | 2019-12-26 | ClinicalTrials.gov |
| NCT03272464 | INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-… | Phase1 | Melanoma | Terminated | 2019-05-29 | 2019-12-27 | ClinicalTrials.gov |
| NCT03571321 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute… | Phase1 | Acute Lymphoblastic Leukemia | Recruiting | 2019-05-28 | 2027-09-05 | ClinicalTrials.gov |
| NCT03952559 | A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Derm… | Phase3 | Atopic Dermatitis | Active_Not_Recruiting | 2019-05-24 | 2026-05-01 | ClinicalTrials.gov |
| NCT03954236 | Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic… | Phase2 | Non-sclerotic Cutaneous Chronic Graft-versus-host Disease | Active_Not_Recruiting | 2019-05-14 | 2027-02-06 | ClinicalTrials.gov |
| NCT03823131 | Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and… | Phase2 | Metastatic Head and Neck Squamous Cell Carcinoma | Terminated | 2019-05-02 | 2022-07-31 | ClinicalTrials.gov |
| NCT03915964 | A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis | Phase4 | Rheumatoid Arthritis | Completed | 2019-04-25 | 2025-05-28 | ClinicalTrials.gov |
| NCT03674047 | Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hemato… | Phase2 | Other Cancer | Active_Not_Recruiting | 2019-04-19 | 2025-12-01 | ClinicalTrials.gov |
| NCT03780166 | A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris | Phase2 | Pemphigus Vulgaris | Withdrawn | 2019-03-01 | 2020-11-01 | ClinicalTrials.gov |
| NCT03627065 | A Study of INCB050465 in Primary Sjögren's Syndrome | Phase2 | Primary Sjögren's Syndrome | Completed | 2019-02-28 | 2020-01-02 | ClinicalTrials.gov |
| NCT03599713 | A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) | Phase2 | Metastatic Merkel Cell Carcinoma | Completed | 2019-02-25 | 2024-06-28 | ClinicalTrials.gov |
| NCT03878199 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Tre… | Phase1 | Essential Thrombocythemia | Terminated | 2019-02-20 | 2025-02-27 | ClinicalTrials.gov |
| NCT03584516 | GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic G… | Phase2 | Chronic Graft-versus-host Disease | Terminated | 2019-01-17 | 2023-11-03 | ClinicalTrials.gov |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | Phase2 | Metastatic Non-small Cell Lung Cancer | Completed | 2019-01-09 | 2022-06-28 | ClinicalTrials.gov |
| NCT03773107 | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory … | Phase1 | Multiple Myeloma | Completed | 2019-01-03 | 2024-02-21 | ClinicalTrials.gov |
| NCT03745638 | Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Eff… | Phase3 | Atopic Dermatitis | Completed | 2018-12-20 | 2020-12-01 | ClinicalTrials.gov |
| NCT03745651 | TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and… | Phase3 | Atopic Dermatitis | Completed | 2018-12-20 | 2020-11-09 | ClinicalTrials.gov |
| NCT03762447 | A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Solid Tumors | Completed | 2018-12-10 | 2023-11-17 | ClinicalTrials.gov |
| NCT03688152 | A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in… | Phase1 | Relapsed Diffuse Large B-Cell Lymphoma | Completed | 2018-12-03 | 2020-09-01 | ClinicalTrials.gov |
| NCT03538041 | A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia | Phase2 | Autoimmune Hemolytic Anemia | Completed | 2018-11-21 | 2024-04-02 | ClinicalTrials.gov |
| NCT03733301 | A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids … | Phase3 | Atopic Dermatitis | Completed | 2018-11-16 | 2019-08-22 | ClinicalTrials.gov |
| NCT03607487 | A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hid… | Phase2 | Hidradenitis Suppurativa | Completed | 2018-10-15 | 2019-08-13 | ClinicalTrials.gov |
| NCT03597295 | A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platin… | Phase2 | Squamous Cell Carcinoma of Anal Canal | Completed | 2018-10-08 | 2021-11-10 | ClinicalTrials.gov |
| NCT03182894 | Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With … | Phase1 | Metastatic Colorectal Cancer | Withdrawn | 2018-09-30 | 2020-07-30 | ClinicalTrials.gov |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | Phase1 | Cervical Cancer | Completed | 2018-09-24 | 2021-08-18 | ClinicalTrials.gov |
| NCT03570749 | A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe A… | Phase2 | Alopecia Areata | Completed | 2018-09-24 | 2025-01-29 | ClinicalTrials.gov |
| NCT03627052 | A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe… | Phase2 | Moderate to Severe Ulcerative Colitis | Withdrawn | 2018-09-20 | 2019-11-13 | ClinicalTrials.gov |
| NCT03681561 | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | Phase1 | Hodgkin Lymphoma | Recruiting | 2018-09-13 | 2027-07-01 | ClinicalTrials.gov |
| NCT03427866 | Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary … | Phase2 | Myelofibrosis | Completed | 2018-08-28 | 2025-05-19 | ClinicalTrials.gov |
| NCT03522142 | A Study Exploring the Safety and Tolerability of INCB081776 in Participants Wit… | Phase1 | Advanced Solid Tumors | Terminated | 2018-08-27 | 2025-09-10 | ClinicalTrials.gov |
| NCT03589651 | INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid… | Phase1 | Unresectable or Metastatic Solid Tumors | Completed | 2018-08-17 | 2022-11-21 | ClinicalTrials.gov |
| NCT03314922 | A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymph… | Phase1 | Lymphoma | Completed | 2018-08-02 | 2023-03-09 | ClinicalTrials.gov |
| NCT03616964 | A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-B… | Phase3 | Systemic Lupus Erythematosus | Completed | 2018-08-02 | 2021-10-20 | ClinicalTrials.gov |
| NCT03616912 | A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythema… | Phase3 | Systemic Lupus Erythematosus | Terminated | 2018-08-02 | 2022-03-09 | ClinicalTrials.gov |
| NCT03569371 | A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurati… | Phase2 | Hidradenitis Suppurativa | Completed | 2018-07-17 | 2019-04-22 | ClinicalTrials.gov |
| NCT03424122 | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibruti… | Phase1 | B-cell Lymphoma | Completed | 2018-07-02 | 2022-06-27 | ClinicalTrials.gov |
| NCT03514407 | A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma | Phase1 | Relapsed Ewing Sarcoma | Terminated | 2018-06-27 | 2020-06-25 | ClinicalTrials.gov |
| NCT03559270 | A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atop… | Phase3 | Atopic Dermatitis | Terminated | 2018-06-27 | 2022-06-13 | ClinicalTrials.gov |
| NCT03153982 | Ruxolitinib in Operable Head and Neck Cancer | Phase2 | Head and Neck Squamous Cell Carcinoma | Terminated | 2018-06-08 | 2023-10-18 | ClinicalTrials.gov |
| NCT03428100 | A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Ad… | Phase3 | Atopic Dermatitis | Completed | 2018-05-15 | 2023-04-20 | ClinicalTrials.gov |
| NCT02928978 | Ruxolitinib for Premalignant Breast Disease | Phase2 | Ductal Carcinoma In Situ | Completed | 2018-05-13 | 2024-09-18 | ClinicalTrials.gov |
| NCT03334435 | A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis | Phase3 | Atopic Dermatitis | Completed | 2018-03-28 | 2023-07-12 | ClinicalTrials.gov |
| NCT03347123 | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Pa… | Phase1 | Solid Tumors | Terminated | 2018-03-21 | 2021-01-29 | ClinicalTrials.gov |
| NCT03497273 | Safety of Itacitinib in Combination With Corticosteroids for Treatment of Stero… | Phase1 | Acute Graft-versus-host Disease | Completed | 2018-03-20 | 2020-02-17 | ClinicalTrials.gov |
| NCT03126019 | A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma | Phase2 | Lymphoma | Completed | 2018-03-14 | 2024-06-07 | ClinicalTrials.gov |
| NCT03361228 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001… | Phase1 | Solid Tumors | Terminated | 2018-03-01 | 2019-03-30 | ClinicalTrials.gov |
| NCT03320642 | GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interv… | Phase1 | Hematologic Malignancies | Terminated | 2018-02-27 | 2022-02-17 | ClinicalTrials.gov |
| NCT03435081 | A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Sever… | Phase3 | Atopic Dermatitis | Completed | 2018-02-20 | 2021-08-16 | ClinicalTrials.gov |
| NCT03006302 | Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Pa… | Phase2 | Metastatic Pancreatic Adenocarcinoma | Completed | 2018-01-31 | 2024-08-05 | ClinicalTrials.gov |
| NCT03144687 | A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Al… | Phase2 | MPN (Myeloproliferative Neoplasms) | Completed | 2018-01-26 | 2021-06-01 | ClinicalTrials.gov |
| NCT02876302 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Neg… | Phase2 | Inflammatory Breast Cancer (IBC) | Active_Not_Recruiting | 2018-01-24 | 2026-04-01 | ClinicalTrials.gov |
| NCT03414229 | A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in… | Phase2 | Sarcoma | Active_Not_Recruiting | 2018-01-23 | 2027-01-01 | ClinicalTrials.gov |
| NCT03322566 | A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Vers… | Phase2 | Lung Cancer | Completed | 2018-01-09 | 2020-10-16 | ClinicalTrials.gov |
| NCT03348904 | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Do… | Phase3 | Lung Cancer | Terminated | 2017-12-27 | 2018-05-22 | ClinicalTrials.gov |
| NCT03374488 | Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progress… | Phase3 | UC (Urothelial Cancer) | Completed | 2017-12-22 | 2020-07-23 | ClinicalTrials.gov |
| NCT03144674 | A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lym… | Phase2 | Lymphoma | Completed | 2017-12-18 | 2024-05-29 | ClinicalTrials.gov |
| NCT03322540 | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-… | Phase2 | Lung Cancer | Completed | 2017-12-15 | 2020-11-09 | ClinicalTrials.gov |
| NCT03342352 | Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME … | Phase3 | Head and Neck Cancer | Withdrawn | 2017-12-15 | 2018-04-20 | ClinicalTrials.gov |
| NCT03260894 | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-6… | Phase3 | Renal Cell Carcinoma (RCC) | Completed | 2017-12-07 | 2025-06-04 | ClinicalTrials.gov |
| NCT03361865 | Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligibl… | Phase3 | UC (Urothelial Cancer) | Completed | 2017-12-04 | 2020-08-04 | ClinicalTrials.gov |
| NCT03358472 | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regi… | Phase3 | Head and Neck Cancer | Completed | 2017-12-01 | 2025-10-30 | ClinicalTrials.gov |
| NCT03334422 | Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Der… | Phase3 | Atopic Dermatitis | Completed | 2017-11-27 | 2018-12-12 | ClinicalTrials.gov |
| NCT03334396 | A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic D… | Phase3 | Atopic Dermatitis | Completed | 2017-11-23 | 2019-08-16 | ClinicalTrials.gov |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects Wi… | Phase1 | Biliary Tract Cancer (BTC) | Completed | 2017-11-21 | 2022-11-28 | ClinicalTrials.gov |
| NCT03235544 | A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously… | Phase2 | Lymphoma | Completed | 2017-11-20 | 2024-04-30 | ClinicalTrials.gov |
| NCT03123588 | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Throm… | Phase2 | MPN (Myeloproliferative Neoplasms) | Terminated | 2017-11-14 | 2020-08-03 | ClinicalTrials.gov |
| NCT03257644 | A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects Wi… | Phase1 | Atopic Dermatitis | Completed | 2017-09-21 | 2020-10-07 | ClinicalTrials.gov |
| NCT03235570 | A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanc… | Phase1 | Solid Tumors | Completed | 2017-08-01 | 2020-03-04 | ClinicalTrials.gov |
| NCT03139604 | GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticostero… | Phase3 | Graft-versus-host Disease (GVHD) | Completed | 2017-07-19 | 2020-07-13 | ClinicalTrials.gov |
| NCT03112603 | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid… | Phase3 | Graft-versus-host Disease (GVHD) | Completed | 2017-06-29 | 2022-12-15 | ClinicalTrials.gov |
| NCT03099304 | A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | Phase2 | Vitiligo | Completed | 2017-06-07 | 2021-09-08 | ClinicalTrials.gov |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Adva… | Phase1 | Hepatocellular Carcinoma (HCC) | Terminated | 2017-05-25 | 2020-06-10 | ClinicalTrials.gov |
| NCT03085914 | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Pa… | Phase1 | Solid Tumor | Completed | 2017-05-02 | 2020-07-13 | ClinicalTrials.gov |
| NCT03011372 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subj… | Phase2 | MPN (Myeloproliferative Neoplasms) | Completed | 2017-04-25 | 2024-10-30 | ClinicalTrials.gov |
| NCT03132324 | A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059… | Phase1 | Sickle Cell Disease | Terminated | 2017-04-20 | 2018-10-03 | ClinicalTrials.gov |
| NCT03117751 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukem… | Phase2 | Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2017-03-29 | 2028-09-30 | ClinicalTrials.gov |
| NCT02998476 | A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or … | Phase2 | Lymphoma | Completed | 2017-03-02 | 2021-02-05 | ClinicalTrials.gov |
| NCT02959437 | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanc… | Phase1 | Solid Tumors | Terminated | 2017-02-27 | 2020-03-02 | ClinicalTrials.gov |
| NCT03069326 | A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination… | Phase2 | Myelofibrosis | Active_Not_Recruiting | 2017-02-27 | 2027-02-01 | ClinicalTrials.gov |
| NCT03039114 | Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine a… | Phase1 | Lymphoma | Completed | 2017-02-15 | 2021-03-30 | ClinicalTrials.gov |
| NCT02718300 | A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofib… | Phase2 | MPN (Myeloproliferative Neoplasms) | Terminated | 2017-02-08 | 2022-04-29 | ClinicalTrials.gov |
| NCT03110822 | A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refracto… | Phase1 | Multiple Myeloma | Recruiting | 2017-02-01 | 2027-02-01 | ClinicalTrials.gov |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surg… | Phase2 | Cholangiocarcinoma | Completed | 2017-01-16 | 2022-02-01 | ClinicalTrials.gov |
| NCT02872714 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subj… | Phase2 | UC (Urothelial Cancer) | Completed | 2017-01-12 | 2022-02-01 | ClinicalTrials.gov |
| NCT03011892 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Appl… | Phase2 | Atopic Dermatitis | Completed | 2017-01-09 | 2018-03-12 | ClinicalTrials.gov |
| NCT02953704 | Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) | — | MPN (Myeloproliferative Neoplasms) | Completed | 2016-12-31 | 2022-03-29 | ClinicalTrials.gov |
| NCT02953678 | A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of… | Phase2 | Graft-versus-host Disease (GVHD) | Completed | 2016-12-30 | 2019-08-14 | ClinicalTrials.gov |
| NCT02760485 | A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects Wi… | Phase1 | Lymphoma | Completed | 2016-12-29 | 2022-06-06 | ClinicalTrials.gov |
| NCT02917993 | An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in … | Phase1 | Lung Cancer | Completed | 2016-12-20 | 2025-12-24 | ClinicalTrials.gov |
| NCT02955940 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previousl… | Phase2 | Pancreatic Cancer | Active_Not_Recruiting | 2016-11-30 | 2027-09-30 | ClinicalTrials.gov |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (B… | Phase2 | Diffuse Large B-cell Lymphoma | Completed | 2016-11-28 | 2024-06-21 | ClinicalTrials.gov |
| NCT03059823 | A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | Phase1 | Locally Advanced Solid Tumors | Completed | 2016-11-15 | 2024-05-22 | ClinicalTrials.gov |
| NCT02723994 | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphob… | Phase2 | Leukemia | Completed | 2016-09-30 | 2026-03-03 | ClinicalTrials.gov |
| NCT02018861 | A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB… | Phase1 | B-Cell Malignancies | Completed | 2016-09-22 | 2021-04-12 | ClinicalTrials.gov |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune … | Phase1 | Metastatic Cancer | Completed | 2016-09-14 | 2022-08-15 | ClinicalTrials.gov |
| NCT02925234 | The Drug Rediscovery Protocol (DRUP Trial) | Phase2 | Cancer | Recruiting | 2016-08-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT02752074 | A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unre… | Phase3 | Melanoma | Completed | 2016-06-21 | 2019-08-16 | ClinicalTrials.gov |
| NCT02711137 | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advance… | Phase1 | Solid Tumors | Terminated | 2016-05-18 | 2019-02-13 | ClinicalTrials.gov |
| NCT02712905 | An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Sub… | Phase1 | Solid Tumors and Hematologic Malignancy | Terminated | 2016-05-05 | 2022-04-14 | ClinicalTrials.gov |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | Phase1 | Recurrent Epithelial Ovarian Cancer | Unknown | 2016-04-01 | 2025-05-01 | ClinicalTrials.gov |
| NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, … | Phase1 | Platinum-resistant Ovarian Cancer | Terminated | 2016-03-08 | 2018-05-08 | ClinicalTrials.gov |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combin… | Phase1 | Colorectal Cancer (CRC) | Completed | 2016-01-25 | 2020-11-20 | ClinicalTrials.gov |
| NCT02587598 | Study of INCB053914 in Subjects With Advanced Malignancies | Phase1 | Solid Tumors | Terminated | 2015-12-29 | 2020-08-11 | ClinicalTrials.gov |
| NCT02614612 | Study of Itacitinib in Combination With Corticosteroids for the Treatment of Ac… | Phase1 | Graft-versus-host Disease (GVHD) | Completed | 2015-12-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT02553330 | A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alo… | Phase2 | Alopecia Areata | Terminated | 2015-11-18 | 2017-10-03 | ClinicalTrials.gov |
| NCT02559492 | Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 … | Phase1 | Solid Tumors | Terminated | 2015-11-01 | 2019-08-18 | ClinicalTrials.gov |
| NCT02494882 | Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remissio… | Phase1 | Acute Lymphoblastic Leukemia | Active_Not_Recruiting | 2015-06-29 | 2026-06-01 | ClinicalTrials.gov |
| NCT02456675 | INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Ref… | Phase2 | Refractory Hodgkin Lymphoma | Terminated | 2015-06-01 | 2016-12-16 | ClinicalTrials.gov |
| NCT02469974 | Ruxolitinib in Combination With Autotransplant | Na | Myelofibrosis | Withdrawn | 2015-05-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02431260 | An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Ma… | Phase1 | Solid Tumors and Hematologic Malignancy | Terminated | 2015-04-14 | 2018-01-31 | ClinicalTrials.gov |
| NCT02364076 | Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | Phase2 | Thymic Carcinoma | Unknown | 2015-03-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Mali… | Phase1 | Lung Cancer | Terminated | 2015-02-27 | 2021-12-17 | ClinicalTrials.gov |
| NCT02298153 | A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previo… | Phase1 | NSCLC (Non-small Cell Lung Carcinoma) | Terminated | 2015-01-27 | 2017-11-08 | ClinicalTrials.gov |
| NCT02318277 | A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) i… | Phase1 | Solid Tumors | Completed | 2015-01-05 | 2020-10-16 | ClinicalTrials.gov |
| NCT01641107 | Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblast… | Phase2 | Philadelphia Positive | Completed | 2014-12-04 | 2021-09-30 | ClinicalTrials.gov |
| NCT02355431 | Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients… | Phase2 | Solid Tumors and Hematologic Malignancy | Withdrawn | 2014-12-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered i… | Phase1 | B-cell Malignancies | Completed | 2014-11-26 | 2020-06-16 | ClinicalTrials.gov |
| NCT02251821 | JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Prima… | Phase2 | Primary Myelofibrosis | Completed | 2014-10-20 | 2026-01-22 | ClinicalTrials.gov |
| NCT02166905 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024… | Phase1 | Fallopian Tube Carcinoma | Completed | 2014-10-10 | 2020-08-20 | ClinicalTrials.gov |
| NCT02257619 | Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Ce… | Phase2 | NSCLC (Non-small Cell Lung Carcinoma) | Terminated | 2014-09-24 | 2016-04-05 | ClinicalTrials.gov |
| NCT02265510 | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients Wit… | Phase1 | Solid Tumors | Terminated | 2014-09-10 | 2019-02-27 | ClinicalTrials.gov |
| NCT02252159 | Prospective Observational Study Of Patients With Polycythemia Vera In US Clinic… | — | MPN (Myeloproliferative Neoplasms) | Completed | 2014-07-31 | 2019-08-03 | ClinicalTrials.gov |
| NCT02118285 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fall… | Phase1 | Ovarian Cancer | Completed | 2014-07-28 | 2015-11-12 | ClinicalTrials.gov |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combinatio… | Phase1 | Microsatellite-instability (MSI) High Colorectal Cancer (CRC) | Completed | 2014-07-17 | 2020-11-06 | ClinicalTrials.gov |
| NCT02155465 | Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarci… | Phase1 | Lung Cancer | Completed | 2014-06-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02119663 | A Study of Ruxolitinib in Pancreatic Cancer Patients | Phase3 | Pancreatic Cancer | Terminated | 2014-06-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02066532 | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast … | Phase1 | Metastatic Breast Cancer | Completed | 2014-06-01 | 2020-10-14 | ClinicalTrials.gov |
| NCT02151474 | INCB047986 in Rheumatoid Arthritis | Phase2 | Rheumatoid Arthritis | Terminated | 2014-05-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02120417 | A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanc… | Phase2 | Breast Cancer | Terminated | 2014-05-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02117479 | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | Phase3 | Pancreatic Cancer | Terminated | 2014-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02119676 | Study of Ruxolitinib in Colorectal Cancer Patients | Phase2 | CRC (Colorectal Cancer) | Terminated | 2014-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02119650 | Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Can… | Phase2 | NSCLC (Non-small Cell Lung Carcinoma) | Terminated | 2014-02-11 | 2016-06-21 | ClinicalTrials.gov |
| NCT02041429 | Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca | Phase1 | Recurrent Breast Cancer | Completed | 2014-02-01 | 2021-01-01 | ClinicalTrials.gov |
| NCT01895842 | Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndro… | Phase1 | Leukemia | Completed | 2014-02-01 | 2019-04-02 | ClinicalTrials.gov |
| NCT02076191 | Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase… | Phase1 | Myeloproliferative Neoplasms | Completed | 2014-02-01 | 2018-07-20 | ClinicalTrials.gov |
| NCT02093429 | Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplas… | Phase1 | MDS (Myelodysplastic Syndrome) | Terminated | 2014-01-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01790295 | Ruxolitinib Prior to Transplant in Patients With Myelofibrosis | Phase2 | Primary Myelofibrosis | Terminated | 2013-11-01 | 2017-10-26 | ClinicalTrials.gov |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | Phase2 | Mucosal Melanoma | Completed | 2013-09-13 | 2017-05-18 | ClinicalTrials.gov |
| NCT01929941 | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients Wit… | Phase1 | Solid Tumor | Terminated | 2013-09-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01822691 | Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS) | Phase2 | Myelodysplastic Syndromes | Completed | 2013-07-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01905813 | Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies | Phase1 | B-cell Malignancies | Completed | 2013-06-30 | 2026-02-26 | ClinicalTrials.gov |
| NCT01858883 | Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab… | Phase1 | Solid Tumors | Completed | 2013-06-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01822756 | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Adv… | Phase1 | Solid Tumors | Terminated | 2013-04-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT01702064 | Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Pat… | Phase1 | Chronic Phase Chronic Myeloid Leukemia | Completed | 2013-02-21 | 2019-01-09 | ClinicalTrials.gov |
| NCT01776723 | A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficac… | Phase1 | Myelomonocytic Leukemia | Completed | 2013-02-20 | 2022-05-10 | ClinicalTrials.gov |
| NCT01730248 | A Study to Find the Maximum Tolerated Dose of the Experimental Combination of t… | Phase1 | Myelofibrosis | Terminated | 2012-12-18 | 2017-09-28 | ClinicalTrials.gov |
| NCT01685255 | A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects … | Phase2 | Ovarian Cancer | Terminated | 2012-08-01 | 2014-10-23 | ClinicalTrials.gov |
| NCT01683409 | A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabeti… | Phase2 | Diabetic Kidney Disease | Completed | 2012-08-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01633372 | An Open Label Study of Itacitinib Administered Orally in Patients With Myelofib… | Phase2 | MPN (Myeloproliferative Neoplasms) | Completed | 2012-07-16 | 2021-06-29 | ClinicalTrials.gov |
| NCT01634087 | A Study of Escalating Doses of Itacitinib Administered Orally in Patients With … | Phase2 | Plaque Psoriasis | Completed | 2012-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01632904 | Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythe… | Phase3 | Polycythemia Vera | Completed | 2012-06-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01604889 | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Comb… | Phase1 | Melanoma | Terminated | 2012-03-29 | 2017-01-20 | ClinicalTrials.gov |
| NCT01626573 | A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Fol… | Phase2 | Rheumatoid Arthritis | Completed | 2012-03-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01536951 | A Study of LY3009104 in Healthy Participants | Phase1 | Healthy Participants | Completed | 2012-02-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01490632 | A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psorias… | Phase2 | Psoriasis | Completed | 2011-12-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01375140 | Ruxolitinib and Lenalidomide for Patients With Myelofibrosis | Phase2 | Myeloproliferative Diseases | Completed | 2011-09-22 | 2018-09-05 | ClinicalTrials.gov |
| NCT01445769 | Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis | Phase2 | Primary Myelofibrosis | Completed | 2011-09-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01423604 | Study of Ruxolitinib in Pancreatic Cancer Patients | Phase2 | Pancreatic Cancer | Completed | 2011-07-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT01398475 | A Relative Bioavailability and Food Effect Study of New Formulations | Phase1 | Chronic Inflammatory Disorder | Completed | 2011-07-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01348490 | Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post… | Phase2 | MPN (Myeloproliferative Neoplasms) | Completed | 2011-06-15 | 2018-12-19 | ClinicalTrials.gov |
| NCT01317875 | Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Pri… | Phase1 | Myelofibrosis | Completed | 2011-03-31 | 2019-12-31 | ClinicalTrials.gov |
| NCT01340651 | Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosi… | Phase2 | Myelofibrosis | Completed | 2011-03-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01251965 | Phase l/II Study of Ruxolitinib for Acute Leukemia | Phase1 | Leukemia | Terminated | 2010-12-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01243944 | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to… | Phase3 | Polycythemia Vera | Completed | 2010-10-27 | 2018-02-09 | ClinicalTrials.gov |
| NCT01247883 | A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In He… | Phase1 | Healthy | Completed | 2010-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01254136 | Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients … | Phase1 | Breast Cancer | Terminated | 2010-10-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01185353 | A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Th… | Phase2 | Arthritis, Rheumatoid | Completed | 2010-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01195311 | A Dose-escalation Study in Subjects With Advanced Malignancies | Phase1 | Solid Tumors and Hematologic Malignancy | Completed | 2010-07-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01072266 | A Dose-escalation Study in Subjects With Advanced Malignancies | Phase1 | Solid Tumor | Completed | 2010-01-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00952289 | COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I… | Phase3 | MPN (Myeloproliferative Neoplasms) | Completed | 2009-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT00902486 | INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Ar… | Phase2 | Rheumatoid Arthritis | Completed | 2009-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00778700 | A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied … | Phase2 | Psoriasis | Completed | 2008-10-28 | 2009-06-26 | ClinicalTrials.gov |
| NCT00726232 | Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polyc… | Phase2 | Myeloproliferative Neoplasm (MPN) | Terminated | 2008-08-20 | 2018-08-20 | ClinicalTrials.gov |
| NCT00674479 | INCB018424 in Patients With Advanced Hematologic Malignancies | Phase2 | Acute Myeloid Leukemia | Completed | 2008-05-12 | 2017-03-23 | ClinicalTrials.gov |
| NCT00698789 | Evaluate the Safety and Tolerability of INCB019602 When Administered With Metfo… | Phase2 | Type 2 Diabetes | Terminated | 2008-05-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00698230 | Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on… | Phase2 | Type 2 Diabetes | Completed | 2008-05-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00639002 | A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inh… | Phase2 | Multiple Myeloma | Completed | 2008-03-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00638378 | Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen… | Phase2 | Prostate Cancer | Terminated | 2008-02-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00550043 | A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of I… | Phase2 | Rheumatoid Arthritis | Completed | 2007-10-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00617994 | Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat … | Phase2 | Psoriasis | Completed | 2007-08-31 | 2009-05-31 | ClinicalTrials.gov |
| NCT00864175 | Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus… | Phase1 | Breast Cancer | Terminated | 2007-07-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00509899 | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Pol… | Phase1 | Myelofibrosis | Completed | 2007-06-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT00820950 | A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Pso… | Phase2 | Psoriasis | Completed | 2007-05-31 | 2009-04-30 | ClinicalTrials.gov |
| NCT00478322 | Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obe… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2007-04-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00398619 | A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Ob… | Phase1 | Insulin Resistance | Completed | 2006-11-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00393120 | Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB00947… | Phase2 | HIV Infections | Completed | 2006-10-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00300573 | Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3… | Phase2 | HIV Infections | Terminated | 2006-04-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00820560 | Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors | Phase1 | Solid Tumors and Hematologic Malignancy | Completed | 2005-01-01 | 2009-01-01 | ClinicalTrials.gov |
Total clinical trials: 454
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pemigatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Afatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Ruxolitinib | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07252050 |
| Extracorporeal Photopheresis | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Axatilimab | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Pemigatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Afatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Ruxolitinib | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07252050 |
| Extracorporeal Photopheresis | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Axatilimab | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Pemigatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Afatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Ruxolitinib | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07252050 |
| Extracorporeal Photopheresis | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Axatilimab | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Pemigatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Afatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Ruxolitinib | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07252050 |
| Extracorporeal Photopheresis | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Axatilimab | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Pemigatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Afatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Ruxolitinib | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07252050 |
| Extracorporeal Photopheresis | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Axatilimab | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Pemigatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Afatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Ruxolitinib | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07252050 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| Ruxolitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| Povorcitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| Extracorporeal Photopheresis | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Axatilimab | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Pemigatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Afatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Ruxolitinib | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07252050 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| Ruxolitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| Povorcitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| Extracorporeal Photopheresis | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Axatilimab | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Pemigatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Afatinib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06302621 |
| Ruxolitinib | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07252050 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| Ruxolitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| Povorcitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| Extracorporeal Photopheresis | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Axatilimab | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | RECRUITING | NCT06663722 |
| Ruxolitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| Povorcitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| Ruxolitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| Povorcitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| Ruxolitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| Povorcitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| Ruxolitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| Povorcitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| Ruxolitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| Povorcitinib | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07588139 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| ruxolitinib | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
| INCB000928 | Other | Phase PHASE1 | Anemia | ACTIVE_NOT_RECRUITING | NCT04455841 |
Total products: 82